Effect of Perioperative Clopidogrel Responsiveness on Ischemic Outcome in Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02184884|
Recruitment Status : Recruiting
First Posted : July 9, 2014
Last Update Posted : January 28, 2019
The whole blood Thrombelastograph (TEG®) Platelet Mapping™ assay measures clot strength, maximal amplitude (MA), reflecting maximal platelet function, and detects the reduction in platelet function, presented as percentage inhibition, by both aspirin and clopidogrel. A study reported that the TEG® can be used as routine monitoring of the variability in ADP receptor inhibition and of antiplatelet therapy. Therefore, using TEG Platelet Mapping assay, we could find out the perioperative clopidogrel responsiveness of the patients with ACS undergoing OPCAB.
The purpose of this study is to determine whether the rate of the major adverse cardiac events (MACE, a combined endpoint of MI, revascularization and cardiac death) is higher in the patients with high degree of clopidogrel resistance, who are scheduled to undergo the OPCAB due to ACS.
|Condition or disease||Intervention/treatment|
|Acute Coronary Syndrome (ACS)||Device: MACE after OPCAB Device: without MACE after OPCAB|
|Study Type :||Observational|
|Estimated Enrollment :||195 participants|
|Study Start Date :||July 2014|
|Estimated Primary Completion Date :||November 2019|
|Estimated Study Completion Date :||November 2019|
the patients with MACE after OPCAB
Device: MACE after OPCAB
no MACE group
the patients without MACE after OPCAB
Device: without MACE after OPCAB
- Rate of the major adverse cardiac events [ Time Frame: at 30 days after surgery ]major adverse cardiac events(MACE) includes the MI, revascularization and cardiac death. Rate of the MACE will be higher in the patients with high degree of clopidogrel resistance.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02184884
|Contact: Jae-Kwang Shim, MDfirstname.lastname@example.org|
|Korea, Republic of|
|Department of Anesthesiology and Pain Medicine||Recruiting|
|Seoul, Korea, Republic of, 120-752|
|Contact: Jae-Kwang Shim, MD 82-10-5065-2733 email@example.com|